Financings in Brief: Orthofix/AME
This article was originally published in The Gray Sheet
Executive Summary
Orthofix/AME: Announce exchange ratio for acquisition of AME by Orthofix ("The Gray Sheet" May 15, p. 12). AME shareholders may choose to receive either $10 in cash for each of their AME shares or 0.579973 shares of Orthofix. The merger is anticipated to be effective on Aug. 21...
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
Irish Body Sets Out Five-Year Vision Strategy For Off-Patent Sector
With a focus on drug accessibility, supply chain resilience, and a balanced approach to sustainability, Medicines for Ireland “calls to action” with its five-year plan.
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.